Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

31.71 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock ↗

August 22, 2022

Via Benzinga

Kymera Therapeutics Stock Scores Rising Relative Price Strength ↗

August 22, 2022

Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94.

Via Investor's Business Daily

Where Genmab Stands With Analysts ↗

August 11, 2022

Genmab (NASDAQ:GMAB) has observed the following analyst ratings within the last quarter:

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates ↗

August 05, 2022

Via Benzinga

Where Genmab Stands With Analysts ↗

June 24, 2022

Analysts have provided the following ratings for Genmab (NASDAQ:GMAB) within the last quarter:

Via Benzinga

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial ↗

June 13, 2022

Via Benzinga

Analyst Ratings for Genmab ↗

May 12, 2022

Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:

Via Benzinga

Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

August 05, 2022

From Genmab A/S

Via Business Wire

AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022 ↗

July 18, 2022

Via Benzinga

Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

July 18, 2022

From Genmab A/S

Via Business Wire

Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom? ↗

July 07, 2022

Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? Is AbbVie stock a buy today

Via Investor's Business Daily

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact ↗

July 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022 ↗

June 24, 2022

Upgrades

Via Benzinga

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

June 11, 2022

From Genmab

Via Business Wire

Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

June 06, 2022

From Seagen Inc.

Via Business Wire

Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

June 06, 2022

From Genmab A/S

Via Business Wire

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2022

From Genmab

Via Business Wire

Johnson & Johnson Stock: A Rare Bright Spot in the Market ↗

May 14, 2022

JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility.

Via InvestorPlace

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

May 12, 2022

From Genmab

Via Business Wire

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022 ↗

May 02, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study ↗

April 14, 2022

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)

Via Benzinga

Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

April 13, 2022

From Genmab A/S

Via Business Wire

BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines ↗

April 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties ↗

April 08, 2022

Via Benzinga

Best Biotech Stocks To Buy In 2022 ↗

March 15, 2022

Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and...

Via Talk Markets

Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

February 24, 2022

From Seagen Inc.

Via Business Wire

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

February 24, 2022

From Genmab A/S

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Genmab A/S - American Depositary Shares (NQ:GMAB)

All News about Genmab A/S - American Depositary Shares

Starting at $3.75/week.

Subscribe Today